Fiera Capital Corp Purchases Shares of 4,341 Abbott Laboratories $ABT

Fiera Capital Corp purchased a new stake in Abbott Laboratories (NYSE:ABT) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,341 shares of the healthcare product maker’s stock, valued at approximately $590,000.

Several other institutional investors have also recently made changes to their positions in ABT. IMG Wealth Management Inc. increased its stake in Abbott Laboratories by 759.1% in the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after buying an additional 167 shares during the last quarter. Elequin Capital LP bought a new stake in shares of Abbott Laboratories during the 1st quarter worth $30,000. Vision Financial Markets LLC purchased a new position in shares of Abbott Laboratories in the 1st quarter worth about $33,000. Accent Capital Management LLC bought a new position in Abbott Laboratories during the first quarter valued at about $38,000. Finally, Curio Wealth LLC increased its holdings in Abbott Laboratories by 15,250.0% during the second quarter. Curio Wealth LLC now owns 307 shares of the healthcare product maker’s stock worth $42,000 after buying an additional 305 shares during the last quarter. Institutional investors own 75.18% of the company’s stock.

Analysts Set New Price Targets

ABT has been the topic of several research analyst reports. Raymond James Financial upped their price objective on Abbott Laboratories from $141.00 to $146.00 and gave the company an “outperform” rating in a research note on Thursday, October 16th. Barclays increased their price target on Abbott Laboratories from $159.00 to $162.00 and gave the stock an “overweight” rating in a research note on Friday, October 17th. BTIG Research reissued a “buy” rating and issued a $145.00 price target on shares of Abbott Laboratories in a research report on Wednesday, October 15th. Wells Fargo & Company lifted their price objective on shares of Abbott Laboratories from $142.00 to $146.00 and gave the company an “overweight” rating in a research note on Thursday, October 16th. Finally, The Goldman Sachs Group increased their target price on Abbott Laboratories from $153.00 to $157.00 and gave the stock a “buy” rating in a research report on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $147.00.

Abbott Laboratories Trading Up 1.0%

Shares of ABT stock opened at $130.59 on Friday. The company has a market capitalization of $227.08 billion, a PE ratio of 16.36, a price-to-earnings-growth ratio of 2.36 and a beta of 0.68. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The business’s fifty day moving average is $130.38 and its 200 day moving average is $131.35. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, meeting the consensus estimate of $1.30. Abbott Laboratories had a return on equity of 17.78% and a net margin of 31.88%.The firm had revenue of $11.37 billion for the quarter, compared to analysts’ expectations of $11.40 billion. During the same quarter last year, the firm posted $1.21 EPS. The company’s revenue was up 6.9% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. On average, equities research analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be paid a dividend of $0.59 per share. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $2.36 annualized dividend and a yield of 1.8%. Abbott Laboratories’s payout ratio is 29.57%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.